Milestone Pharmaceuticals (MIST) Reports Q3 Loss, Beats Revenue Estimates
MIST posted a narrower-than-expected Q3 loss and a sharp revenue beat, but the stock remains deeply underwater and carries a bearish quant rating.
Milestone Pharmaceuticals (MIST) reported a Q3 loss of $0.18 per share, better than the consensus estimate of a $0.20 loss. That works out to a 10% earnings surprise.
Revenue was the bigger headline. MIST booked $2.96 million, topping estimates by 161.52%. A year ago, the company reported zero revenues, so the top line moved from nothing to a measurable figure in twelve months.
The price action tells a different story. MIST has fallen 67.6% year-to-date, a drawdown that the quarterly beat does not erase. Zacks Investment Research assigns the stock a Rank #4 (Sell), citing unfavorable estimate revisions. In our interpretation, that rating suggests analysts have been trimming forward expectations even as the company clears the current-quarter bar.
The disconnect is the setup: a double beat on EPS and revenue against a stock down roughly two-thirds on the year and a Sell-ranked estimate trend. IVVD is also tagged to this earnings coverage, though the supplied reporting contains no IVVD-specific figures.